natgillin/translations-raw huggingface dataset:
Noxafil must not be administered with medicinal products that are substrates for CYP3A4 and are known to prolong the QTc interval (see sections 4.3 and 4.5). 
Zdravila Noxafil se ne sme uporabljati skupaj z zdravili, ki so substrati CYP3A4 in za katere je znano, da podaljšajo interval QTc (glejte poglavji 4.3 in 4.5).
Therefore, inhibitors (e.g. verapamil, ciclosporin, quinidine, clarithromycin, erythromycin, etc.) or inducers (e.g. rifampicin, rifabutin, certain anticonvulsants, etc.) of these clearance pathways may increase or decrease posaconazole plasma concentrations, respectively. 
Zato lahko zaviralci (npr. verapamil, ciklosporin, kinidin, klaritromicin, eritromicin, itd.) ali induktorji (npr. rifampicin, rifabutin, določeni antikonvulzivi, itd.) teh poti izločanja povečajo ali zmanjšajo koncentracije posakonazola v plazmi.
• have an abnormal heart rhythm tracing (ECG) that shows a problem called long QTc interval 
• če imate nenormalen zapis srčnega ritma (EKG), ki kaže motnjo, imenovano podaljšanje intervala QTc.
However, in clinical efficacy trials, the safety profile of posaconazole between the young and elderly patients was similar. 
V kliničnih preskušanjih učinkovitosti pa je bil profil varnosti posakonazola pri starostnikih podoben kot pri mlajših bolnikih.
• hair loss (alopecia) 
• izpadanje las (alopecija)
Based on the available data in 16 of these paediatric patients, the safety profile appears to be similar to patients ≥ 18 years of age. 
Na podlagi razpoložljivih podatkov za 16 od teh pediatričnih bolnikov je varnostni profil zdravila videti podoben kot pri bolnikih, starih ≥ 18 let.
No clinically relevant changes in the mean QTc (Fridericia) interval from baseline were observed. 
V primerjavi z izhodiščem niso opazili klinično pomembnih sprememb povprečnega intervala QTc (Fridericia).
• adrenal glands not working properly - this may cause weakness, tiredness, loss of appetite, skin discolouration 
• nepravilno delovanje nadledvičnih žlez - to lahko povzroči šibkost, utrujenost, izgubo apetita,
• some patients have also reported feeling confused after using Noxafil. 
• nekateri bolniki so po uporabi zdravila Noxafil poročali tudi o občutku zmedenosti.
Based on the pharmacokinetics and safety results of Cohorts 1 and 2, all subjects in Cohort 3 received 300 mg twice daily on Day 1, followed by 300 mg once daily thereafter. 
Na podlagi rezultatov o farmakokinetiki in varnosti v kohortah 1 in 2 so vsi preiskovanci v kohorti 3 dobili 300 mg dvakrat na dan 1. dan in nato 300 mg enkrat na dan.
It is particularly important to try to ensure that maximal plasma levels are achieved in patients infected with Aspergillus (see sections 4.2 and 5.2 on recommended dose regimens). 
Posebej pomembno je, da poskušamo zagotoviti, da pri bolnikih, okuženih z Aspergillusom, dosežemo največje plazemske koncentracije (glejte poglavji 4.2 in 5.2 o priporočenih režimih odmerjanja).
Posaconazole is highly protein bound (> 98 %), predominantly to serum albumin. 
Posakonazol je v veliki meri vezan na beljakovine (> 98 %), predvsem na serumski albumin.
Gastro-resistant tablet (tablet) Yellow-coated, capsule-shaped tablet of 17.5 mm length debossed with “100” on one side. 
gastrorezistentna tableta (tableta) Rumena, obložena tableta v obliki kapsule, dolga 17,5 mm in z vtisnjeno oznako "100" na eni strani.
When initiating treatment with posaconazole in patients already receiving ciclosporin, the dose of ciclosporin should be reduced (e.g. to about three quarters of the current dose). 
Na začetku zdravljenja s posakonazolom je treba bolnikom, ki že prejemajo ciklosporin, odmerek ciklosporina zmanjšati (npr. na približno tri četrtine trenutnega odmerka).
This medicinal product contains 462 mg (20 mmol) sodium per dose. 
To zdravilo vsebuje 462 mg (20 mmol) natrija na odmerek.
In a study in healthy volunteers posaconazole oral suspension (200 mg once daily for 10 days) increased the exposure (AUC) of intravenous midazolam (0.05 mg/kg) by 83 %. 
V študiji pri zdravih prostovoljcih je peroralna suspenzija posakonazola (200 mg enkrat na dan 10 dni) povečala izpostavljenost (AUC) intravensko uporabljenemu midazolamu (0,05 mg/kg) za 83 %.
Patients were treated with posaconazole or fluconazole oral suspension (both posaconazole and fluconazole were given as follows: 100 mg twice a day for 1 day followed by 100 mg once a day for 13 days). 
Bolnike so zdravili s posakonazolom ali s peroralno suspenzijo flukonazola (tako posakonazol kot flukonazol so odmerjali na naslednji način: 100 mg dvakrat na dan 1 dan, potem pa 100 mg enkrat na dan 13 dni).
Thromboembolic events 
Tromboembolični dogodki
As shown in Table 4, a successful response (complete or partial resolution) at the end of treatment was seen in 42 % of posaconazole-treated patients compared to 26 % of the external group. 
Kot prikazuje preglednica 4, je bil uspešen odziv (popolno ali delno izginotje) ob koncu zdravljenja opazen pri 42 % bolnikov, zdravljenih s posakonazolom, in pri 26 % bolnikov iz zunanje skupine.
Noxafil can increase the amount of these medicines in the blood which may lead to a severe decrease in blood flow to your fingers or toes and could cause damage to them. 
Zdravilo Noxafil lahko poveča koncentracijo teh zdravil v krvi; to lahko zelo zmanjša dotok krvi v prste rok in nog in lahko povzroči njihovo okvaro.
• large purple discolourations on the skin (thrombotic thrombocytopenic purpura) 
• obsežna vijolična obarvanja kože (trombotična trombocitopenična purpura)
The following medicines may decrease the effectiveness of Noxafil by decreasing the amount of Noxafil in the blood: 
Naslednja zdravila lahko zmanjšajo učinkovitost zdravila Noxafil, ker zmanjšajo njegovo količino v krvi:
• halofantrine (used to treat malaria) 
• halofantrin (za zdravljenje malarije)
• loss of appetite, stomach pain or upset stomach, passing wind, dry mouth, changes in your taste 
• izguba apetita, bolečine v želodcu ali razdražen želodec, vetrovi, suha usta, spremembe okusa
Posaconazole increased Cmax and AUC of tacrolimus (0.05 mg/kg body weight single dose) by 121 % and 358 %, respectively. 
Posakonazol je povečal Cmax takrolimusa (enkratni odmerek 0,05 mg/kg telesne mase) za 121 % in njegovo AUC za 358 %.
If it is considered that co-administration is unavoidable, then it is recommended that the dose of sirolimus should be greatly reduced at the time of initiation of posaconazole therapy and that there should be very frequent monitoring of trough concentrations of sirolimus in whole blood. 
Če se sočasni uporabi ni mogoče izogniti, je ob uvedbi zdravljenja s posakonazolom priporočljivo zelo zmanjšati odmerek sirolimusa in zelo pogosto preverjati najnižjo koncentracijo sirolimusa v polni krvi.
• diltiazem, verapamil, nifedipine, nisoldipine or other “calcium channel blockers” (used to treat high blood pressure) 
• diltiazem, verapamil, nifedipin, nizoldipin in drugi zaviralci kalcijevih kanalčkov (uporabljajo se za zdravljenje visokega krvnega tlaka),
In subjects with severe renal impairment (n=6, Cl cr < 20 mL/min/1.73 m2), the AUC of posaconazole was highly variable [> 96 % CV (coefficient of variance)] compared to other renal groups [< 40 % CV]. 
Pri preiskovancih s hudo okvaro ledvic (n = 6, očistek kreatinina < 20 ml/min/1,73 m2) je bila AUC posakonazola močno spremenljiva [koeficient variacije (KV) > 96 %] v primerjavi z drugimi kategorijami delovanja ledvic [KV < 40 %].
renal tubular acidosis, interstitial nephritis 
ledvična tubularna acidoza, intersticijski nefritis
Cav = the average concentration when measured at steady state *20 patients received 200 mg once daily (Day 1 200 mg twice daily) 
Cav = povprečna koncentracija, merjena v stanju dinamičnega ravnovesja *20 bolnikov je prejemalo 200 mg enkrat na dan (200 mg dvakrat na dan 1. dan)
Tablet coat polyvinyl alcohol macrogol 3350 titanium dioxide (E171) talc iron oxide yellow (E172) 
Obloga tablete polivinilalkohol makrogol 3350 titanov dioksid (E171) smukec rumeni železov oksid (E172)
If you forget to take Noxafil 
Če ste pozabili vzeti zdravilo Noxafil
) was prolonged from approximately 27 hours up to ~43 hours in respective groups. 
27 ur na vse do približno 43 ur.
The effect of posaconazole on CYP3A4 substrates in patients might be somewhat lower than that observed in healthy volunteers, and is expected to be variable between patients due to the variable posaconazole exposure in patients. 
Učinek posakonazola na substrate CYP3A4 je lahko pri bolnikih nekoliko manjši kot pri zdravih prostovoljcih in mogoče je pričakovati, da se od bolnika do bolnika razlikuje zaradi različne stopnje izpostavljenosti posakonazolu.
Thrombophlebitis was observed in clinical trials. 
V kliničnih preskušanjih so opazili tromboflebitis.
Noxafil gastro-resistant tablets are packaged in a blister in cartons of 24 (2x12) or 96 (8x12) tablets. 
Noxafil gastrorezistentne tablete so pakirane v pretisnih omotih v škatlah, ki vsebujejo po 24 (2 x 12) ali 96 (8 x 12) tablet.
• severe allergic reactions, including widespread blistering rash and skin peeling 
• hude alergijske reakcije, vključno z izpuščajem z mehurji in lupljenje kože po celem telesu
If not used immediately, the solution can be stored up to 24 hours refrigerated 2°C-8°C. 
Če ni uporabljeno takoj, je mogoče raztopino shranjevati do 24 ur, shranjeno v hladilniku pri temperaturi od 2 °C do 8 °C.
As shown in Table 3, a successful response (complete or partial resolution) at the end of treatment was seen in 42 % of posaconazole-treated patients compared to 26 % of the external group. 
Kot prikazuje preglednica 3, je bil uspešen odziv (popolno ali delno izginotje) ob koncu zdravljenja opazen pri 42 % bolnikov, zdravljenih s posakonazolom, in pri 26 % bolnikov iz zunanje skupine.
Quartile pCav Range (ng/mL) 
Razpon pCav (ng/ml)
The effect of co-administration with posaconazole on plasma levels of CYP3A4 substrates may also be variable within a patient, unless posaconazole is administered in a strictly standardised way with food, given the large food effect on posaconazole exposure (see section 5.2). 
Učinek sočasne uporabe posakonazola na plazemske koncentracije substratov CYP3A4 se lahko razlikuje tudi pri posameznem bolniku, razen če prejme posakonazol na strogo standardiziran način s hrano, glede na velik vpliv hrane na izpostavljenost posakonazolu (glejte poglavje 5.2).
The safety of posaconazole oral suspension has been assessed in > 2,400 patients and healthy volunteers enrolled in clinical trials and from post-marketing experience. 
Varnost peroralne suspenzije posakonazola so ocenili pri > 2.400 bolnikih in zdravih prostovoljcih, vključenih v klinična preskušanja, in na podlagi izkušenj med obdobjem trženja.
Co-administration may result in increased plasma concentrations of these medicinal products, leading to QTc prolongation and rare occurrences of torsades de pointes (see section 4.3). 
Sočasna uporaba lahko povzroči povečanje koncentracije teh zdravil v plazmi, kar vodi do podaljšanja intervala QTc in v redkih primerih povzroči torsades de pointes (glejte poglavje 4.3).
• swelling, redness, and tenderness along the vein in which Noxafil was given 
• oteklost, pordelost in občutljivost vzdolž vene, v katero ste dobili zdravilo Noxafil
300 mg once daily (Day 1 300 mg twice daily)* 
300 mg enkrat na dan (1. dan 300 mg dvakrat na dan)*
abnormal dreams, confusional state, sleep disorder psychotic disorder, depression 
nenormalne sanje, zmedenost, motnje spanja psihotična motnja, depresija
§, electrocardiogram abnormal palpitations, bradycardia, supraventricular extrasystoles, tachycardia 
§, nenormalen elektrokardiogram palpitacije, bradikardija, supraventrikularne ekstrasistole, tahikardija
Posaconazole may increase the plasma concentrations of vinca alkaloids which may lead to neurotoxicity and other serious adverse reactions. 
Posakonazol lahko zviša plazemsko koncentracijo alkaloidov vinke kar lahko vodi do nevrotoksičnosti in drugih resnih neželenih učinkov.
In Table 3 a comparison is shown of exposure (Cav) after administration of posaconazole tablet and posaconazole oral suspension at therapeutic doses in patients depicted as quartile analysis. 
Preglednica 3 prikazuje primerjavo izpostavljenosti (Cav) po uporabi tablet posakonazola in peroralne suspenzije posakonazola v terapevtskih odmerkih pri bolnikih, predstavljeno z analizo kvartilov.
• a change in the salt level in your blood shown in blood tests - signs include feeling confused or weak 
• sprememba koncentracije soli v krvi, ki se pokaže na preiskavah krvi - med znaki sta občutek zmedenosti ali šibkost
The excreted metabolites in urine and faeces account for approximately 17 % of the administered radiolabelled dose. 
V urinu in blatu izločeni presnovki zajemajo približno 17 % uporabljenega radioaktivno označenega odmerka.
The mean duration of therapy was 29 days for posaconazole and 25 days for fluconazole/itraconazole. 
Zdravljenje s posakonazolom je trajalo povprečno 29 dni in s flukonazolom/itrakonazolom 25 dni.
Non-Interchangeability between Noxafil Tablets and Noxafil Oral Suspension 
Medsebojna nezamenljivost Noxafil tablet in Noxafil peroralne suspenzije
When administered through a peripheral venous catheter, the infusion should be administered over approximately 30 minutes (see section 4.8 and 6.6). 
Če je zdravilo dano po perifernem venskem katetru, mora infundiranje trajati približno 30 minut (glejte poglavji 4.8 in 6.6).
Noxafil is a white, cherry flavoured, 105 mL oral suspension packaged in amber glass bottles. 
Noxafil je bela 105 ml peroralna suspenzija z okusom češnje, pakirana v stekleničke iz rjavega stekla.
Co-administration with the CYP3A4 substrates terfenadine, astemizole, cisapride, pimozide, halofantrine or quinidine since this may result in increased plasma concentrations of these medicinal products, leading to QTc prolongation and rare occurrences of torsades de pointes (see sections 4.4 and 4.5). 
Sočasna uporaba s substrati CYP3A4 terfenadinom, astemizolom, cisapridom, pimozidom, halofantrinom ali kinidinom, ker lahko poveča plazemske koncentracije teh zdravil, kar pa lahko povzroči podaljšanje intervala QTc in redko tudi torsades de pointes (glejte poglavji 4.4 in 4.5).
See “Other medicines and Noxafil” below for information on other medicines which may interact with Noxafil. 
Glejte "Druga zdravila in zdravilo Noxafil" (spodaj) za več informacij o drugih zdravilih, ki lahko medsebojno delujejo z zdravilom Noxafil.
• a blockage in your gut (intestinal obstruction) especially in the “ileum”. 
• zapora črevesa (intestinalna obstrukcija), zlasti v delu, imenovanem "ileum".
Therefore, reserve azole antifungals, including posaconazole, for patients receiving a vinca alkaloid, including vincristine, who have no alternative antifungal treatment options. 
Azolski antimikotiki, vključno s posakonazolom, naj bodo zato rezervirani za bolnike, ki prejemajo alkaloid vinke, vključno z vinkristinom, in ki nimajo alternativnih možnosti protiglivnega zdravljenja.
• severe sharp chest pain when breathing in (pleurritic pain) 
• hude, ostre bolečine v prsih pri vdihu (plevritične bolečine)
• menstrual problems (abnormal vaginal bleeding) 
• težave z menstruacijo (nenormalna krvavitev iz nožnice)
• shivering, feeling generally unwell 
• drgetanje, splošno slabo počutje
Co-administration of posaconazole and ergot alkaloids is contraindicated (see section 4.3). 
Sočasna uporaba posakonazola in alkaloidov ergot je kontraindicirana (glejte poglavje 4.3).
If a central venous catheter was not readily available, patients could receive a single infusion over 30 minutes via a peripheral venous catheter. 
Če centralni venski kateter ni bil na voljo, so bolniki lahko dobili enkratno 30-minutno infuzijo po perifernem venskem katetru.
Adverse reactions by body system and frequency reported in clinical trials and/or postmarketing use* 
Neželeni učinki, razvrščeni po organskih sistemih in pogostnosti, o katerih so poročali v kliničnih preskušanjih in/ali v obdobju trženja*
No further increases in exposure were observed when doses above 800 mg daily were administered to patients and healthy volunteers. 
Pri dajanju odmerkov nad 800 mg na dan bolnikom in zdravim prostovoljcem niso opažali nobenega nadaljnjega povečanja izpostavljenosti zdravilu.
200 mg four times daily (hospitalized) then 400 mg twice daily 
200 mg štirikrat na dan (hospitalizirani), nato 400 mg dvakrat na dan
Co-administration of posaconazole with H2 receptor antagonists should be avoided if possible. 
Sočasni uporabi posakonazola in antagonistov receptorjev H2 se je treba izogibati, če je le mogoče.
Following single-dose administration of posaconazole oral suspension, there was no effect of mild and moderate renal impairment (n=18, Cl cr ≥ 20 mL/min/1.73 m2) on posaconazole pharmacokinetics; therefore, no dose adjustment is required. 
Po enkratnem odmerku peroralne suspenzije posakonazola blaga in zmerna okvara ledvic (n = 18, očistek kreatinina ≥ 20 ml/min/1,73 m2) nista vplivali na farmakokinetiko posakonazola, zato prilagoditev odmerka ni potrebna.
Duration of therapy should be based on the severity of the underlying disease, recovery from immunosuppression, and clinical response. 
Trajanje zdravljenja je odvisno od resnosti bolnikove osnovne bolezni, okrevanja po imunosupresiji in bolnikovega kliničnega odziva.
• have a very slow heartbeat 
• če imate zelo počasno bitje srca.
Type I glass vial closed with bromobutyl rubber stopper and aluminium seal containing 16.7 mL of solution. 
Viala iz stekla tipa I, zaprta z zamaškom iz brombutilne gume in aluminijasto zaporo; viala vsebuje 16,7 ml raztopine.
• some patients have also reported feeling confused after taking Noxafil. 
• nekateri bolniki so po jemanju zdravila Noxafil poročali tudi o občutku zmedenosti.
You may feel dizzy, sleepy, or have blurred vision while taking Noxafil, which may affect your ability to drive or use tools or machines. 
Med uporabo zdravila Noxafil ste lahko omotični, zaspani ali imate zamegljen vid, kar lahko vpliva na vašo sposobnost upravljanja vozil in strojev.
Patients who have severe diarrhoea or vomiting should be monitored closely for breakthrough fungal infections. 
Bolnike, ki imajo hudo drisko ali bruhajo, je treba skrbno spremljati glede prebijajočih (breakthrough) glivnih okužb.
Concomitant administration of azole antifungals, including posaconazole, with vincristine has been associated with neurotoxicity and other serious adverse reactions, including seizures, peripheral neuropathy, syndrome of inappropriate antidiuretic hormone secretion, and paralytic ileus. 
Sočasna uporaba azolskih antimikotikov, vključno s posakonazolom, in vinkristina je bila povezana z nevrotoksičnostjo in drugimi resnimi neželenimi učinki, vključno z epileptičnimi napadi, periferno nevropatijo, sindromom neustreznega izločanja antidiuretskega hormona in paralitičnim ileusom.
In a nonclinical study using intravenous administration of posaconazole in very young dogs (dosed from 2-8 weeks of age) an increase in the incidence of brain ventricle enlargement was observed in treated animals as compared with concurrent control animals. 
V predklinični študiji intravenske uporabe posakonazola pri zelo mladih psih (ki so zdravilo prejemali v starosti od 2 do 8 tednov) so pri živalih, ki so dobivale zdravilo, opazili večjo pojavnost povečanja možganskih prekatov kot pri sočasnih kontrolnih živalih.
Alternatively, if recommended by your doctor, you may take 400 mg (two 5 mL spoonfuls) twice a day provided that you are able to take both doses during or after food or a nutritional drink. 
Druga možnost je, če vam tako svetuje zdravnik, da zaužijete po 400 mg (dve polni 5 ml žlički) suspenzije dvakrat na dan, če imate možnost, da ta dva odmerka vzamete med ali takoj po jedi ali zaužitju prehranskega dopolnila v obliki napitka.
• Congenital or acquired QTc prolongation 
• kongenitalno ali pridobljeno podaljšanje intervala QTc,
Patients with a low body weight (< 60 kg) are more likely to experience higher plasma concentrations of posaconazole and should be closely monitored for adverse events. 
Bolniki z majhno telesno maso (< 60 kg) imajo večjo verjetnost za povečane koncentracije posakonazola v plazmi in jih je treba skrbno spremljati glede neželenih učinkov.
What Noxafil looks like and contents of the pack 
Izgled zdravila Noxafil in vsebina pakiranja
Posaconazole, after administration of the tablet, has a mean apparent volume of distribution of 394 L (42 %), ranging between 294-583 L among the studies in healthy volunteers. 
Po uporabi tablet je povprečni navidezni volumen porazdelitve posakonazola 394 l (42 %) in v študijah pri zdravih prostovoljcih sega od 294 do 583 l.
Patients were enrolled in a non-comparative pharmacokinetic and safety trial of posaconazole concentrate for solution for infusion when given as antifungal prophylaxis (Study 5520). 
Bolnike so vključili v neprimerjalno preskušanje farmakokinetike in varnosti posakonazola v koncentratu za raztopino za infundiranje, uporabljenega za antimikotično profilakso (študija 5520).
Patients, in particular those receiving posaconazole after HSCT, who have a low body weight (< 60 kg) are more likely to experience higher plasma concentrations of posaconazole and should be closely monitored for adverse events. 
Bolniki, zlasti tisti, ki prejemajo posakonazol po presaditvi hematopoetskih celic in imajo majhno telesno maso (< 60 kg), imajo večjo verjetnost za povečane koncentracije posakonazola v plazmi in jih je treba skrbno spremljati glede neželenih učinkov.
In heart transplant patients on stable doses of ciclosporin, posaconazole oral suspension 200 mg once daily increased ciclosporin concentrations requiring dose reductions. 
Pri bolnikih s presajenim srcem, ki prejemajo stabilne odmerke ciklosporina, je peroralna suspenzija posakonazola v odmerku 200 mg enkrat na dan povečala koncentracijo ciklosporina, tako da je bilo potrebno zmanjšanje njegovega odmerka.
Noxafil concentrate for solution for infusion requires dilution (see section 6.6) prior to administration. 
Zdravilo Noxafil koncentrat za raztopino za infundiranje je treba pred uporabo razredčiti (glejte poglavje 6.6).
As HIV protease inhibitors are CYP3A4 substrates, it is expected that posaconazole will increase plasma levels of these antiretroviral agents. 
Zaviralci proteaze HIV so substrati CYP3A4, zato se pričakuje, da bo posakonazol povečal plazemsko koncentracijo teh protiretrovirusnih zdravil.
Serum creatinine levels should be closely monitored in these patients (see section 4.4). 
Pri teh bolnikih je treba natančno kontrolirati koncentracijo kreatinina v serumu (glejte poglavje 4.4).
In healthy volunteers under fasting conditions, dividing the total daily dose (800 mg) into 200 mg four times daily compared to 400 mg twice daily, was shown to increase posaconazole exposure by 2.6-fold. 
Pri zdravih prostovoljcih na tešče so pokazali, da razdelitev celotnega dnevnega odmerka (800 mg) na 200 mg štirikrat na dan v primerjavi s 400 mg dvakrat na dan poveča izpostavljenost posakonazolu za 2,6-krat.
Thromboembolic events have been identified as a potential risk for posaconazole intravenous concentrate for solution for infusion but were not observed in the clinical studies. 
Obstaja potencialno tveganje tromboemboličnih dogodkov pri uporabi posakonazola v obliki intravenskega koncentrata za raztopino za infundiranje, vendar ga v kliničnih študijah niso opazili.
• astemizole (used to treat allergies) 
• astemizol (za zdravljenje alergij)
Noxafil is also available for oral administration (Noxafil 100 mg gastro-resistant tablets and 40 mg/mL oral suspension). 
Zdravilo Noxafil je na voljo tudi za peroralno uporabo (Noxafil 100 mg gastrorezistentne tablete in 40 mg/ml peroralna suspenzija).
• Glipizide or other “sulfonylureas” (used to treat high blood sugar). 
• glipizid ali druge sulfonilsečnine (uporabljajo se za zdravljenje zvišanega sladkorja v krvi).
Among eighteen patients who were intolerant or had infections refractory to amphotericin B or itraconazole, seven patients were classed as responders. 
Med osemnajstimi bolniki, ki niso prenašali amfotericina B ali itrakonazola ali ki so imeli okužbe, odporne na amfotericin B ali itrakonazol, so jih sedem uvrstili med odzivne na zdravljenje.